NOAC for ESUS - ATTICUS and ARCADIA - Prof. Tobias Geisler and Prof. Hooman Kamel

Prof. Tobias Geisler and Prof. Hooman Kamel - who are Principle Investigators or the ATTICUS and ARCADIA trials, respectively, which have been published in NEJM Evidence and JAMA in early 2024 - discuss antithrombotic treatment in patients with Embolic Stroke of Undetermined Source (ESUS).

Professor Tobias Geisler is Cardiologist at Eberhard Karls University Tübingen and Deputy Director of the Medical Clinic III of University Hospital Tübingen, Germany. He is PI of the ATTICUS study, which compared Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.

Professor Hooman Kamel is Neurologist, Chief of the Division of Neurocritical Care and Director of the Clinical and Translational Neuroscience Unit in the Department of Neurology and the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine.
He is PI of the ARCADIA study, which compared apixaban to aspirin in subjects with cryptogenic ischemic stroke and atrial cardiopathy.

The interview was recorded on March 11th, 2024.

Moderators: Prof. Christoph Kleinschnitz (Essen, Germany), Prof. Stephan Schirmer (Kaiserslautern, Germany) and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).

Articles discussed:

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.
Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, Aragón García R, Plummer P, Sabagha N, Pauls Q, Cassarly C, Dillon CR, Di Tullio MR, Hod EA, Soliman EZ, Gladstone DJ, Healey JS, Sharma M, Chaturvedi S, Janis LS, Krishnaiah B, Nahab F, Kasner SE, Stanton RJ, Kleindorfer DO, Starr M, Winder TR, Clark WM, Miller BR, Elkind MSV; ARCADIA Investigators
JAMA 2024
doi: 10.1001/jama.2023.27188

Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.
Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, Gawaz M, Tünnerhoff J, Bombach P, Nägele T, Klose U, Aidery P, Groga-Bada P, Kraft A, Hoffmann F, Hobohm C, Naupold K, Niehaus L, Wolf M, Bäzner H, Liman J, Wachter R, Kimmig H, Jung W, Huber R, Feurer R, Lindner A, Althaus K, Bode FJ, Petzold GC, Nguyen TN, Mac Grory B, Schrag M, Purrucker JC, Zuern CS, Ziemann U, Poli S; ATTICUS Investigators
NEJM Evid 2024
doi: 10.1056/EVIDoa2300235

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H; External reviewers.
Europace 2021
doi: 10.1093/europace/euab065

EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.
Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D'Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S
Heart Rhythm 2017
doi: 10.1016/j.hrthm.2016.05.028

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group
Eur Heart J. 2021
doi: 10.1093/eurheartj/ehaa612